Levetiracetam therapeutic monitoring in patients with epilepsy: Effect of concomitant antiepileptic drugs

Therapeutic Drug Monitoring

Volumn 26, Issue 4, 2004, Pages 375-379

  Contin, Manuela ^a   Albani, Fiorenzo ^a   Riva, Roberto ^a   Baruzzi, Agostino ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Antiepileptic drug kinetic interaction; Levetiracetam; Levetiracetam toxicity; Therapeutic drug monitoring

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; CLOBAZAM; CYTOCHROME P450; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROIC ACID;

ADULT; ARTICLE; COHORT ANALYSIS; CONFUSION; CONTROLLED STUDY; DIZZINESS; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG MONITORING; EPILEPSY; ERYTHEMA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SEX DIFFERENCE; SIDE EFFECT; SOMNOLENCE; SPECTROPHOTOMETRY; STEADY STATE;

ADULT; ANTICONVULSANTS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; MALE; PIRACETAM; PROSPECTIVE STUDIES;

EID: 3342885956     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200408000-00006     Document Type: Article

References (12)

1. Patsalos PN. Levetiracetam. Chemistry, biotransformation, pharmacokinetics, and drug interactions. In: Levy RH, Mattson RH, Meldrum BS. Perucca E, eds. Antiepileptic Drugs. Philadelphia: Lippincott Williams & Wilkins, 2002:428-432.
2. Patsalos PN. The pharmacokinetics characteristics of levetiracetam. Methods Find Exp Clin Pharmacol. 2003;25:123-129.
3. Perucca E, Baltes E, Ledent E. Levetiracetam: Absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs). Epilepsia. 2000;41(Suppl 6):150.
4. Welty TE, Gidal BE, Ficker DM, et al. Levetiracetam: A different approach to the pharmacotherapy of epilepsy. Ann Pharmacother. 2002;36: 296-304.
5. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res. 2003;53:47-56.
6. Riva R, Albani F, Contin M, et al. Pharmacokinetic interactions between antiepileptic drugs: clinical considerations. Clin Pharmacokinet. 1996; 31:470-493.
7. Coupez R, Nicolas J-M, Browne TR. Levetiracetam, a new antiepileptic agent: Lack of in vitro and in vivo pharmacokinetic interaction with valproic acid. Epilepsia. 2003;44:171-178.
8. Ratnaraj N, Doheny HC, Patsalos PN. A micromethod for the determination of the new antiepileptic drug levetiracetam (ucb L059) in serum or plasma by high performance liquid chromatography. Ther Drug Monit. 1996;18:154-157.
9. Ren S, Scheuer ML, Zheng W. Determination of lamotrigine in biological materials by a simple and rapid liquid chromatography method. Ther Drug Monit. 1998;20:209-214.
10. Nicolas J-M, Collart P, Gerin B, et al. In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic agent. Drug Metab Dispos. 1999;27:250-254.
11. Sisodiya SM, Sander JWAS, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res. 2002;48:217-219.
12. Betts T, Yarrow H, Greenhill L, et al. Clinical experience of marketed levetiracetam in an epilepsy clinic - a one year follow up study. Seizure. 2003;12:136-140.